<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               WARNING: BLEEDING RISK<BR><BR>               <BR>                  <BR>                     Effient can cause significant, sometimes fatal, bleeding<BR><BR>                     [see Warnings and Precautions (5.1 and 5.2) and Adverse Reactions (6.1)].<BR>                  <BR>                  <BR>                     Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke<BR><BR>                     [see Contraindications (4.1 and 4.2)].<BR>                  <BR>                  <BR>                     In patients ≥75 years of age, Effient is generally not recommended, because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk situations (patients with diabetes or a history of prior MI) where its effect appears to be greater and its use may be considered<BR><BR>                     [see Use in Specific Populations (8.5)].<BR><BR>                  <BR>                     Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.<BR>                  <BR>                  <BR>                     Additional risk factors for bleeding include:<BR>                  <BR>                  <BR>                     <BR>                        body weight <60 kg<BR>                     <BR>                     <BR>                        propensity to bleed<BR>                     <BR>                     <BR>                        concomitant use of medications that increase the risk of bleeding (e.g., warfarin, heparin, fibrinolytic therapy, chronic use of non-steroidal anti-inflammatory drugs [NSAIDs])<BR>                     <BR>                  <BR>                  <BR>                     Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient.<BR>                  <BR>                  <BR>                     If possible, manage bleeding without discontinuing Effient. Discontinuing Effient, particularly in the first few weeks after acute coronary syndrome, increases the risk of subsequent cardiovascular events<BR><BR>                     [see Warnings and Precautions (5.3)].<BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           WARNING: BLEEDING RISK<BR>                        <BR>                        <BR>                           See full prescribing information for complete boxed warning<BR>                        <BR>                        <BR>                           Effient can cause significant, sometimes fatal, bleeding (5.1, 5.2, and 6.1).<BR>                        <BR>                        <BR>                           Do not use Effient in patients with active pathological bleeding or a history of transient ischemic attack or stroke (4.1 and 4.2).<BR>                        <BR>                        <BR>                           In patients ≥75 years of age, Effient is generally not recommended because of the increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk patients (diabetes or prior MI), where its effect appears to be greater and its use may be considered (8.5).<BR>                        <BR>                        <BR>                           Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue Effient at least 7 days prior to any surgery.<BR>                        <BR>                        <BR>                           Additional risk factors for bleeding include:<BR>                        <BR>                        <BR>                           <BR>                              body weight <60 kg<BR>                           <BR>                           <BR>                              propensity to bleed<BR>                           <BR>                           <BR>                              concomitant use of medications that increase the risk of bleeding<BR>                           <BR>                        <BR>                        <BR>                           Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient.<BR>                        <BR>                        <BR>                           If possible, manage bleeding without discontinuing Effient. Stopping Effient, particularly in the first few weeks after acute coronary syndrome, increases the risk of subsequent cardiovascular events (5.3).<BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>